Aspr-17-03390 -- janssen influenza portfolio -- advanced development candidates (other transactional authority)

Ended Indefinite Delivery Contract Awarded Last action

Contract number
HHSO100201700018C
Awardee
Awarding agency
Task orders
0

Award facts

Last date to order 100% complete
IDV ceiling
$919,512,953.00
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

This Indefinite Delivery Contract was awarded on August 15, 2017, by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services, to Janssen Pharmaceuticals, Inc. (UEI: RDJSZL3THV47) as a single award with no set-aside provisions. The contract, identified as ASPR-17-03390, has a ceiling value of $919.5 million and is scheduled for completion by December 31, 2025. The contract was executed under Other Transactional Authority, which provides the federal government flexibility in contracting mechanisms to support advanced research and development activities outside traditional procurement regulations.

The contract encompasses advanced development candidates within Janssen's influenza portfolio, supporting ASPR's mission to advance medical countermeasures and pandemic preparedness capabilities. The scope includes development and advancement of influenza vaccine and therapeutic candidates through the advanced development phase. The contract structure as an indefinite delivery vehicle allows for flexibility in funding and task issuance as development milestones and requirements evolve. A bilateral modification was subsequently executed to descope work and deobligate funds, consistent with transparency requirements regarding federal spending management. This engagement reflects the federal government's strategic investment in expanding the pharmaceutical industry's capacity to develop broadly protective influenza countermeasures for pandemic preparedness and response.

Transactions

Action Obligated Date
Change Order P00020 · EOI::EO: radical transparency about wasteful spending::EOI bilateral modification to descope work and deobligate funds. -$100,000,000
Other Administrative Action P00019 -$241,626,561
Other Administrative Action P00018 · Janssen influenza portfolio and other emerging pathogens development candidates $0
Supplemental Agreement for work within scope P00017 · The purpose of this amendment is to updated SOW reflects discussions held by both parties during the in-process review (IPR) on may 4, 2021, and the resulting… $0
Supplemental Agreement for work within scope P00016 $0
Other Administrative Action P00015 · The purpose of this amendment is to make bilateral changes within the general scope of this agreement to (i) relinquish USG?s ownership interest in 8,320… $0
Other Administrative Action P00014 · The purpose of this amendment makes bilateral changes within the general scope of this agreement to (i) relinquish USG?s ownership interest in 100,000 vials… $0
Funding Only Action P00013 · The purpose of this amendment is to update the scope of WP 6.17 related to covid-19 vaccine r & d efforts. In addition, option WPS 6.11 & 6.112 have been… $31,998,326
Other Administrative Action P00012 · This amendment 12 agreement makes bilateral changes within the general scope of this agreement to (i) relinquish USG's ownership interest in 150,000 vials of… $0
Supplemental Agreement for work within scope P00011 $454,310,546
Change Order P00010 · This amendment, based on joint oversight committee (JOC) recommendation, documented in memo #12 dated 16 june 2020, and in accordance with article IV of the… $85,304,775
Other Administrative Action P00009 · Administrative modification to align funded amount on agreement for reporting consistency on external facing data reporting websites (beta.SAM.GOV / fpds) $0
Supplemental Agreement for work within scope P00008 · Addition of new vaccine asset for 2019 novel coronavirus (covid-19) $456,237,081
Supplemental Agreement for work within scope P00007 · Addition of new antiviral / therapeutic asset for 2019 novel coronavirus (covid-19) $148,373,126
Supplemental Agreement for work within scope P00006 · Addition of new asset for 2019 novel corona virus (covid), budget restructure to fund new asset from existing uniflu funding, addition of program management… $0
Other Administrative Action P00005 · Realignment of budget structure, statement of work. $0
Other Administrative Action 4 $0
Exercise an Option 3 $41,327,515
Supplemental Agreement for work within scope 2 $0
Supplemental Agreement for work within scope 1 $0
Original award $43,588,145
Show all 21

Quick answers

Who was awarded contract HHSO100201700018C?

HHSO100201700018C was awarded to Janssen Pharmaceuticals, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on August 15, 2017.

How much is contract HHSO100201700018C worth?

HHSO100201700018C's own ceiling is $919,512,953.

Who can order from contract HHSO100201700018C?

HHSO100201700018C is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract HHSO100201700018C competed?

The extent of competition for HHSO100201700018C was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login